PULSECARE is an innovative medical device company with industry-leading multi-modal energy platforms and key technologies such as pulsed electric field, ultrasound and radio frequency. At present, PULSECARE has arranged a variety of therapeutic innovative medical device products for indications such as cardiac electrophysiology, liver tumor and refractory hypertension, and based on the research accumulation of the team for more than 20 years, it has broken through multiple "cut-throat" problems in the industry and obtained better clinical efficacy and safety.

Within two years of its establishment, PULSECARE has efficiently developed three therapeutic medical device products. Among them, the world's first third-generation nanosecond pulsed electric field ablation (nsPFA) atrial fibrillation treatment product has been enrolled in clinical trials in multiple centers nationwide, and the efficacy and technical advantages of the product have been highly recognized by clinical experts; The multi-modal pulsed electric field tumor ablation product solves a series of technical problems existing in the current "nano-knife"(irreversible electroporation tumor ablation product). The ultrasonic renal artery sympathetic nerve ablation system (RDN) is the only ultrasonic RDN system in the industry that can realize ultrasonic nerve mapping and ablation. The registration clinical trial of the above two products will be carried out soon.

Based on its multi-modal energy platform technology, the Company can realize rapid design, manufacturing and iterative upgrading of products, product pipeline layout planning cardiac electrophysiology, ultrasound RDN, RF energy platform, plasma energy platform, etc. The Company has mastered a series of key core technologies, has achieved complete independent R&D and production of innovative products, and has large-scale production capacity of platform-based equipment and consumables.